AbbVie shares took a hit Friday after costs related to the drugmaker’s acquisition of Apogee Therapeutics forced a cut to its full-year profit outlook. Second-quarter revenue jumped 10% to nearly $17 billion, beating the $16.8 billion consensus estimate among analysts polled by FactSet. AbbVie posted adjusted earnings of $3.65 a share, narrowly ahead of Wall Street’s call for $3.60.
News
High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
Moby summary of Altria Group, Inc.'s Q2 2026 earnings call
Moby summary of Intercontinental Exchange, Inc.'s Q2 2026 earnings call
Moby summary of Eversource Energy's Q2 2026 earnings call
Robinhood Markets (Nasdaq: HOOD) reported its earnings for the second quarter of 2026 on July 29. The brokerage platform, popular for its equity, crypto, and tokenized stock offerings, generated $1.31 billion in revenue and $0.62 in earnings per share (EPS), beating Wall ...
Adjusted earnings of $12 billion, or $6.06 per share, beat analyst estimates by 50 cents as higher oil and refining margins drove results
Investing.com -- AbbVie Inc. (NYSE: ABBV) reported second-quarter earnings before the open on Friday, missing profit expectations, although revenue beat the consensus estimate.
The e-commerce and cloud giant topped second quarter expectations as accelerating cloud growth at Amazon Web Services (AWS) helped drive strong results.
The e-commerce and cloud giant topped second quarter expectations as accelerating cloud growth at Amazon Web Services (AWS) helped drive strong results.
The company said refunds were limited because it stockpiled inventory ahead of tariffs and is not the importer of record for most goods in its store
Moderna (MRNA) delivered earnings and revenue surprises of 0.00% and +14.49%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Investing.com -- Novo Nordisk (NYSE: NVO) shares dropped 10% Friday after the drugmaker revealed its experimental drug, ziltivekimab, failed to cut cardiovascular risk in a late-stage clinical trial.
KKR & Co. Inc. (NYSE:KKR) reported record second-quarter results for 2026, led by growth in management fees, fundraising, capital deployment and monetization activity across its asset management, insurance and strategic holdings businesses. Fee-related earnings were $1.32 per share, up 34% from a y
Jones Lang LaSalle (NYSE:JLL) reported second-quarter 2026 revenue growth of 11% in U.S. dollars and 10% in local currency, supported by broad strength in its advisory operations and continued growth in recurring-service businesses. Adjusted EBITDA rose 33% and adjusted earnings per share increased
KBR (NYSE:KBR) reported second-quarter 2026 revenue of approximately $2 billion, up 2% from the prior-year period, while adjusted EBITDA rose $16 million to $258 million and adjusted EPS increased $0.08 to $0.99. The company said first-half results were tracking slightly ahead of its planned cadence
Kinross Gold (NYSE:KGC) reported second-quarter production of 492,000 gold equivalent ounces and attributable free cash flow of $727 million, as the company said it remains on track to meet its 2026 production, cost and capital-spending guidance. Chief Executive Officer Paul Rollinson said the comp
The stock was down 9.5% after the company’s experimental medicine ziltivekimab didn’t achieve the expected risk reduction for major cardiovascular events.
Stock Market Today: The Dow Jones index rises Friday even as Apple dives on a weak sales forecast. Amazon stock surges on earnings.
The Federal Reserve held rates steady Wednesday, but the bond market pushed borrowing costs sharply higher, sending the 30-year Treasury yield to its highest level since 2007. Peter Schiff says the selloff exposed the gap between Kevin Warsh’s words and...
The Wall Street Journal reports some Tesla executives have been told to prepare for a separation of the company's China operations
Shares of Coinbase Global slipped 5.6% in premarket trading on Friday after a third straight quarterly loss, though analysts expect strong fundamentals and business diversity to cushion it from a crypto cycle downturn. The cryptocurrency market lost significant value in recent sessions, with bitcoin falling, as expectations that the U.S. Federal Reserve will cut interest rates faded and investors pulled money from spot exchange-traded funds. Shares of Coinbase, often tied to the crypto cycle, have matched that with a nearly 28% decline.
Moderna narrowed its loss in the recent quarter as revenue climbed, boosted by deliveries made under a government contract in the U.K.
Find insight on Sanofi, Haleon, Cochlear and more in the latest Market Talks covering the health care sector.
Chevron saw profits surge in the second quarter on soaring prices for refined products.
Exxon (XOM) delivered earnings and revenue surprises of -4.35% and +21.10%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Eaton (ETN) delivered earnings and revenue surprises of +2.27% and +6.57%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Cameco (CCJ) delivered earnings and revenue surprises of -50.00% and +10.04%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Find insight on Ferrari, Stellantis, Air France-KLM and more in the latest Market Talks covering the auto and transport sector.
Investing.com -- Colgate-Palmolive Company (NYSE:CL) reported second-quarter earnings before the open on Friday, topping earnings expectations.
In crypto news today (July 30), Bitcoin climbed -0.5% overnight, dropping below $64,000 following yesterday’s FOMC meeting, in which a rate hike wasn’t announced but SEC Chair Paul Atkins hinted at hikes to come, causing a slight sell-off across crypto. However, crypto held up well in comparison to the US ...